Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

Infectious Agents and Cancer

Volumn 11, Issue 1, 2016, Pages

  Rosenthal, Elana S ^a   Graham, Camilla S ^b,c  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Group14 Engineering   (United States)

Author keywords

Cost effectiveness; Direct acting antivirals; Hepatitis C virus; Pharmaceutical pricing

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG INDUSTRY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEPATITIS C; HUMAN; MEDICAID; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; UNITED STATES;

EID: 85007478352     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-016-0071-z     Document Type: Review

References (33)

1. Hepatitis C. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. [Accessed 8/27/2015].
2. Centers for Disease Control and Prevention. Notes from the field: risk factors for hepatitis C virus infections among young adults - Massachusetts, 2010. In: MMWR. 2011. p. 1457-8.
3. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men New York City, 2005-2010. In: MMWR. 2011. p. 945-50.
4. Simmons B et al. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015; 61(5):730-40.
5. Afdhal N et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93.
6. Afdhal N et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-98.
7. Cousien A et al. Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2015; 63(4):1090-101.
8. Trooskin SB, Reynolds H, Kostman JR. Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy. Clin Infect Dis. 2015;61(12):1825-30.
9. Van Nuys K et al. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Aff (Millwood). 2015;34(10): 1666-74.
10. Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens. Available from: http://www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment. [Accessed 10/20/15].
11. The Health Strategies Consultancy Prepared for the Kaiser Family Foundation. Follow The Pill: Understanding the U.S. Commercia Pharmaceutical Supply Chain. 2005. p. 32.
12. Congressional Budget Office. Prescription Drug Pricing in the Private Sector. 2007. p. 26.
13. Silverman E. U.S. Could Save up to $16B if Medicare Part D Prices are Negotiated: Paper. NYC, NY: The Wall Street Journal Blog; 2015
14. Center for Medicare Advocacy. Part D/Prescription Drug Benefits. Available from: http://www.medicareadvocacy.org/medicare-info/medicare-part-d/-covered%20drugs. [Accessed 10/28/15].
15. Pollack A. Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion. NYC, NY: The New York Times; 2015.
16. Silverman, E. What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean. NYC, NY: The Wall Street Journal; 2015
17. Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015;119:89-96.
18. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015;3(2): e73-4.
19. World Health Organization. Cost-Containment Mechanisms for Essential Medicines, Including Antiretrovirals, in China - Health Economics and Drugs Series No. 013, Essential Medicines and Health Products Information Portal - A World Health Organization resource. 2003.
20. Gilead Sciences. CHRONIC HEPATITIS C TREATMENT EXPANSION Generic Manufacturing for Developing Countries. 2015.
21. Bristol-Myers Squibb. HCV Developing World Strategy. 2015.
22. Doctors Without Borders. Gilead Denied Patent for Hepatitis C Drug Sofosbuvir in India. 2015.
23. Borders DW China Rejects Gilead Patent on Hepatitis C Drug Sofosbuvir 6/19/2015. Available from http://www.doctorswithoutborders.org/article/china-rejects-gilead-patent-hepatitis-c-drug-sofosbuvir. Accessed 3/6/2016.
24. Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. 2016. [epub ahead of print]
25. Najafzadeh M et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6)407-19.
26. Leidner AJ et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860-9.
27. Linas BP et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162(9):619-29.
28. Everson GT et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015;163(11):818-26.
29. Feld JJ et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-607.
30. Foster GR et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608-17.
31. Barua S et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med. 2015;163(3):215-23.
32. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C 2015.
33. Silverman E. Gilead Limits Enrollment in its Hep C Patient Programs to Pressure Insurers. NYC, NY: The Wall Street Journal Blog; 2015.